How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Preclinical CRO Treatment Market
- By Service Type: In Vivo Pharmacology, Toxicology Studies, ADME (Absorption, Distribution, Metabolism, Excretion) Studies, Biomarker Discovery and Validation, Safety Pharmacology
- By Therapeutic Area: Oncology, Cardiovascular, Neurology, Infectious Diseases, Immunology
- By Animal Model Type: Rodent Models, Non-Rodent Models, Transgenic Models, Disease-Specific Models, Large Animal Models
- By Study Phase: Dose Range Finding, Repeat Dose Toxicity, Genotoxicity, Carcinogenicity, Reproductive Toxicity
- By End-User: Pharmaceutical Companies, Biotechnology Firms, Academic Research Institutions, Government Research Organizations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In Vivo Pharmacology leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 310 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Preclinical CRO Treatment Market report
A complete, evidence-based study - 12 chapters and 130 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Therapeutic Area 5
Animal Model Type 5
Study Phase 5
End-User 4
Companies profiled
Charles River Laboratories International Inc.
Labcorp Drug Development (Covance)
ICON plc
PPD
Inc. (Thermo Fisher Scientific)
WuXi AppTec
Envigo (part of Inotiv)
Eurofins Scientific
QPS Holdings
LLC
MPI Research (now part of Charles River)
Frontage Laboratories Inc.
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PPD
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Inc. (Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Envigo (part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Eurofins Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →QPS Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MPI Research (now part of Charles River)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Frontage Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BioDuro
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Toxikon Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Absorption Systems
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Vivotecnia
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inotiv
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$972.6M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In Vivo Pharmacology59.6
- Toxicology Studies6.8
- ADME (Absorption, Distribution, Metabolism, Excretion) Studies12.8
- Biomarker Discovery and Validation13.7
- Safety Pharmacology7.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$180.0M → $306.7M · 6.9%
Europe$125.5M → $226.9M · 7.7%
Asia Pacific$114.5M → $183.7M · 6.1%
Latin America$70.9M → $140.4M · 8.9%
Middle East and Africa$54.5M → $86.4M · 5.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.442026
7.462027
7.472028
7.492029
7.492030
7.512031
7.522032
7.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.11.8
- Labcorp Drug Development (Covance)18.4
- ICON plc11.3
- PPD5.9
- Inc. (Thermo Fisher Scientific)11.9
- WuXi AppTec12.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type15.1%
Therapeutic Area22.4%
Animal Model Type31.1%
Study Phase19.6%
End-User11.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe24.0
- Asia Pacific19.5
- Latin America14.9
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 82 | 84 | 88 | 82 | 82 | 79 | 83 |
| Labcorp Drug Development (Covance) | 83 | 93 | 93 | 75 | 76 | 79 | 83 |
| ICON plc | 86 | 62 | 64 | 73 | 73 | 74 | 72 |
| PPD | 75 | 82 | 69 | 58 | 80 | 74 | 73 |
| Inc. (Thermo Fisher Scientific) | 55 | 66 | 76 | 70 | 56 | 69 | 65 |
| WuXi AppTec | 51 | 48 | 52 | 70 | 48 | 51 | 53 |
| Envigo (part of Inotiv) | 53 | 64 | 64 | 53 | 61 | 46 | 57 |
| Eurofins Scientific | 55 | 57 | 39 | 35 | 53 | 53 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Labcorp Drug Development (Covance)
- ICON plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Labcorp Drug Development (Covance) | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| ICON plc | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| PPD | ✓ | ✓ | − | ◐ | ✓ | ✓ |
| Inc. (Thermo Fisher Scientific) | − | ✓ | ◐ | ◐ | − | − |
| WuXi AppTec | ◐ | − | − | − | − | − |
| Envigo (part of Inotiv) | − | ◐ | ◐ | ◐ | − | ◐ |
| Eurofins Scientific | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.83
2Labcorp Drug Development (Covance)83
3PPD73
4ICON plc72
5Inc. (Thermo Fisher Scientific)65
6Envigo (part of Inotiv)57
7WuXi AppTec53
8Eurofins Scientific49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Labcorp Drug Development (Covance)
Challenger2
Strong scale, closing on the leaders.
ICON plcPPD
Contender2
Focused players with pockets of strength.
Inc. (Thermo Fisher Scientific)Envigo (part of Inotiv)
Niche2
Specialists in a single segment or region.
WuXi AppTecEurofins Scientific
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Preclinical CRO Treatment Market — a $415M beachhead inside a $6.02B market.
Beachhead (SOM)$415Mobtainable near-term
Serviceable (SAM)$2.53Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
In Vivo Pharmacology
Best fit — highest urgency & budget in Service Type.
Economic buyer76 fit
Toxicology Studies
Strong fit — clear ROI and a fast path to value.
End user64 fit
ADME (Absorption, Distribution, Metabolism, Excretion) Studies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Animal Model Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Preclinical CRO Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified26%
Evaluation13%
Closed-won7%
$14.8KCAC
$77KLTV
5.2:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Preclinical CRO Treatment Market is a resilient opportunity — $6.83B by 2033, compounding at 3.5%.
TAM · 2025$5.18Btoday
TAM · 2033$6.83Bforecast
CAGR3.5%2027–2033
Cumulative$53.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.83BTotal addressable market
SAM$2.60BServiceable available market
SOM$505MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.5% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.83BLarge & growingTAM by 2033 at 3.5% CAGR
$2.60BServiceable nowreachable with today’s model
$505MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.33BBear2.3% CAGR
$6.83BBase3.5% CAGR
$8.74BBull4.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Preclinical CRO Treatment Market — a $8.90B market by 2033. Plan: grow share from 8.2% to 12.7%.
Market size · 2033$8.90Btotal addressable
Market CAGR7.9%2027–2033
Target share12.7%from 8.2% today
Revenue ambition$1.13Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.2% | 12.7% | Ahead |
| Revenue | $725M | $1.13B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.4% | 44.9% | Behind |
| Customer retention | 91.2% | 92.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $139M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Preclinical CRO Treatment Market conversation — a $1.23B market you can size, segment and defend in minutes.
Market size · 2033$1.23Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,278+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 2 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Labcorp Drug Development (Covance)ICON plcPPDInc. (Thermo Fisher Scientific)WuXi AppTecEnvigo (part of Inotiv)Eurofins Scientific+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Preclinical CRO Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Preclinical CRO Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hysteroscopic Endometrial Resection Procedures Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View report3D Printed Drugs Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportLixisenatide Market
Market size, share, segmentation and regional forecast.
$785M market · 2025 base year
View reportMedical Finger Cots Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportDermal Filler and Botolinum Toxin Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportGlycosylated Hemoglobin and C Peptide Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSickle Cell Disease Treatment Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportPulmonary Dilation Balloon Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportSeasonal Influenza Vaccines Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportScoliosis Management Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportChicken Vaccines Market
Market size, share, segmentation and regional forecast.
$364M market · 2025 base year
View reportPorcine Vaccines Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.